Navigation Links
New research may show why some prostate cancer recurs after treatment
Date:10/11/2007

Lake Tahoe, CA, October 11, 2007 Cancer researchers have long worked to understand why some prostate cancers recur after the use of therapies designed to stop the production of testosterone and other androgens that fuel cancer cell growth. New research has now detected that androgen-synthesizing proteins are present within cancer cells, which suggests that cancer cells may develop the capacity to produce their own androgens.

The presence of these proteins may explain why some prostate cancers become resistant to these widely-used therapies, and offers new directions for research into future treatments that could block the development of androgens in the cancer cells. The study, funded by the Prostate Cancer Foundation and the National Cancer Institute, was presented today at the Foundations annual Scientific Retreat.

Androgen-deprivation therapy is routinely used in the treatment of advanced (metastatic) prostate cancer, in order to deprive cancer cells of these hormones that fuel their growth. However, over time cancer cells can become androgen independent, and grow even in the presence of these medications. This type of the cancer is a lethal form of the disease, with most patients dying 18 to 24 months after becoming resistant to hormone suppression. Research in the field has focused on understanding the mechanisms used by these cancer cells to become castration resistant.

Investigators Peter Nelson, M.D., Elahe Mostaghel, M.D., Ph.D., and Bruce Montgomery, M.D. from the Fred Hutchinson Cancer Research Center and University of Washington, conducted tests on tumors removed and preserved from deceased prostate cancer patients during rapid autopsies immediately after death. All the patients had received androgen-blocking therapies during the course of treatment to suppress tumor growth.

The researchers were able to detect in the tumors the key proteins, or enzymes, needed for a cell to produce its own testosterone from
'/>"/>

Contact: Sharon Reis
prostate@gymr.com
202-745-5100
GYMR
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related medicine news :

1. Kidney Stones - Interesting New Research implicates bacteria as its cause
2. Stem cell research- now Nobel Laureates join the debate
3. Researchers urge caution in using ear tube surgery
4. Paracetamol May Cause Live Damage Warns Consumer Education and Research Centre
5. Spouses and other partners lower blood pressure says new research
6. Researchers Scale to assess the Severity of Epilepsy in Kids
7. More Research Required For COPD
8. Researchers identify the early makers of Neonatal Sepsis
9. OHSU Researchers Announce New Discovery
10. Skin Cancer Research To Go Global
11. Researchers Identify Gene Connected To Bipolar Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/6/2008)...ospital Ship Serving in West Africa Receives Acces...ley, Texas October 6, 2008 -- www.seamobile.com [S... of communications services to remote locations, a...oxNews channel via satellite to Mercy Ships onboar... The Africa Mercy is the world,s largest non-gove...
(Date:10/5/2008)...iderable disparities in survival related to race a...and neck cancer. Published in the November 15, 200...e American Cancer Society, the study indicates tha...t could improve outcomes for these cancers among A...dies have examined disparities in cancer survival ...
(Date:10/5/2008)...ifficult to kill a spider as it scurries across th...er set foot on a plane. While nothing physically ...r can keep them from the task at hand. , The sam...hysical activity, according to research presented ... , Researchers from the Center for Obesity Resea...
(Date:10/3/2008)...ide Komen Community Challenge Campaign to Close,th...come Women and Women of ... Pennsylvania House Speaker Dennis,O,Brien (R-169t... survivors,and advocates from the Philadelphia Aff...ic forum this morning to call for policies to clos...
Breaking Medicine News(10 mins):Health News:Seamobile Provides Foxnews To Mercy Ships 2Health News:Seamobile Provides Foxnews To Mercy Ships 3Health News:News from Cancer: Disparities in head and neck cancer patients 2Health News:Mental barriers hamper obese women's efforts to get exercise 2Health News:Susan G. Komen for the Cure(R), Speaker Dennis O'Brien, Obama and McCain Health Care Advisors, Breast Cancer Survivors and Advocates Call for Needed Health Care Reforms 2Health News:Susan G. Komen for the Cure(R), Speaker Dennis O'Brien, Obama and McCain Health Care Advisors, Breast Cancer Survivors and Advocates Call for Needed Health Care Reforms 3
... obesity rates are soaring as well.Studies say tha...e world by the end of the decade and raise the ris...010 the number of overweight and obese youngsters ...ould be 26 million. Over a million children will ...
...wn are growing in number, and this has led to a no...40’s desirous of having a child are going to be gi...th Service.// Hospital administration is re-worki...ren without their partners. Camden primary care tr...
...nternational, two major pharma companies, agreed t...d flu that will cater to the needs of Indian and S...harat Biotech will fund all pre-clinical and clini... responsible for the commercialisation of the sing...
...tyle like regular exercise and nutritious diet can... other researchers at John Hopkins// Bloomberg Sch... erectile dysfunction (ED) from more than 2,200 ad...as collected from participants in the US governmen...
Other Medicine News:Health News:Pharma Companies Tie Up To Develop Bird Flu Vaccine 2
(Date:10/6/2008)... - Data Presented at ACG Annual Scientific Confer...nwood Pharmaceuticals,(formerly Microbia) today an...nical studies delineating the role that cyclic gua...ntestinal pain. These studies,demonstrate that cGM...of,intestinal hyperalgesia and desensitizes coloni...
(Date:10/6/2008)...lts from Phase 3b Studies with Durezol Dosed Prior...Sirion Therapeutics, Inc., a,privately held ophtha...today that Durezol(TM) (difluprednate ophthalmic e...zol, which was approved by the U.S. Food and,Drug ...ic corticosteroid,indicated for the treatment of i...
(Date:10/6/2008)...than 60 percent of moderate to severe patients ach... achieved endoscopic remission at Week 10,in data ...merican College,of Gastroenterology (ACG) Annual S...ire/ -- UCB today presented data from a,large, pro...t in Crohn,s,disease (CD) with a biologic compound...
(Date:10/6/2008)...LE, Oct. 6 /- Dendreon Corp... today, Monday, October 6, 2008 at 9:00 AM,ET (6:0...ysis of its IMPACT,(IMmunotherapy for Prostate Ade...cal trial of PROVENGE(R) (sipuleucel-T), the Compa... for the treatment of advanced prostate,cancer., ...
Breaking Medicine Technology:Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain 2Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain 3Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 2Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 3Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 4Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 5CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 2CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 3CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 4CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 5CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 6CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 7Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial 2Protein Tomography 28TM 29 Reveals Molecular Mode of Action of Humax EGFr Published in PNAS 1869 1Protein Tomography 28TM 29 Reveals Molecular Mode of Action of Humax EGFr Published in PNAS 1869 2Survey 3A Employers Have High Confidence They Can Control Health Care Costs With Proper Tools 17389 1Survey 3A Employers Have High Confidence They Can Control Health Care Costs With Proper Tools 17389 2Survey 3A Employers Have High Confidence They Can Control Health Care Costs With Proper Tools 17389 3TopoTarget Successfully Buys Back Full Control of Belinostat 4752 1TopoTarget Successfully Buys Back Full Control of Belinostat 4752 2TopoTarget Successfully Buys Back Full Control of Belinostat 4752 3TopoTarget Successfully Buys Back Full Control of Belinostat 4752 4TopoTarget Successfully Buys Back Full Control of Belinostat 4752 5TopoTarget Successfully Buys Back Full Control of Belinostat 4752 6TopoTarget Successfully Buys Back Full Control of Belinostat 4752 7Mannatech Launches Business in South Africa 17387 1Mannatech Launches Business in South Africa 17387 2Mannatech Launches Business in South Africa 17387 3
...Presentation Details Statistically Significant Cli...ent of Diabetic Neuropathy, CHICAGO, June 22, 2007...c. announced today the presentation of encouraging...) program at the,67th Scientific Sessions of the A...n an oral presentation entitled, "Improved,Neurolo...
... FOSTER CITY, Calif.--(BUSINESS WIRE)--June 25, 20...unced that Study 103, a,Phase III clinical trial e...iread(R) (tenofovir disoproxil fumarate or tenofov... hepatitis B virus,(HBV) infection, met its primar...non-inferior to the company,s once-daily antiviral...
Other Medicine Technology:Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 2Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 3Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 4Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 5Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 6Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 7Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 8Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 9Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 2Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 3Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 4Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 5Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 6
...rt SI inserter from Bausch & Lomb provides fingert...ned for one handed delivery of the IOL directly in...assured by planar delivery. Leading haptic is posi...bag without sweeping motion. No additional instrum...
...erex Ultra Q is the fundamental capsulotmy laser -...ergy delivery and provides 2855% less energy in ai... in contemporary systems. This technology elimina...educes the risk of IOL pitting. , , , Ultr...
Protects the eye during or after surgery or trauma. Clear window dressing. Protects the eye allowing the patient to see.
Product designed specifically for posteror segment surgical procedures. For dissection of vitreoretinal membrames using viscoelastic fluid. A high pressure luer lock tubing set is attached to cannula
Medicine Products: